Therapeutic strategies aimed at targeting this novel STAT3/SLUG pathway may prove particularly effective at blocking this transition, prevent or delay recurrence, and ultimately significantly improve survival of GBM patients. This evidence concerns the gene SNAI2 and glioblastoma.